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Introduction: Injuries and/or dysfunctions in the somatosensory system can lead to neuropathic pain. Transient receptor potential 
vanilloid sub‑type 1 (TRPV1) play an important role in the development of allodynia and hyperalgesia following injury and the ensuing 
inflammatory conditions. Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 agonist and many different administration routes are 
available for different mechanisms and different effects. RTX is used intraperitonially as a model of neuropathic pain or epidurally and 
topically to produce prolonged analgesic effects. However, the use of RTX is controversial because its neurotoxicity and margin of safety 
have not been addressed adequately. The present study evaluates the effect of intrathecal RTX on the induction and allodynia behavior 
of animals submitted to neuropathic pain by chronic constriction injury (CCI). Methods: 160 Swiss mice were randomly distributed 
into two groups: intrathecal pre‑treatment group (PRE) aiming the effect in induction of allodynia and late intrathecal treatment group 
(POST) to evaluate the antiallodynic effect of the RTX on mechanical nociceptive threshold evaluated by the Von Frey hair filaments. 
Additionally, we evaluated the expression of TRPV1 in dorsal root ganglia (DRG) by western blotting after PRE‑ and POST‑treatment 
with RTX. Results: Our results showed that the CCI mice developed prolonged mechanical allodynia‑like behavior in ipsilateral paw 
after surgery up to 24 hours. The PRE‑ and POST‑treatment groups presented significant antiallodynic effects in ipsilateral paw for 
24 hours. Only the POST‑treatment group showed a significant reduction of expression of the TRPV1 receptor after CCI. Conclusion: The 
presented data demonstrated that both PRE‑ and POST‑treatment with RTX given intrathecally produced potent antiallodynic activities 
in CCI mice and that POST‑treatment can reduce TRPV1 expression in DRG, suggesting that POST‑treatment RTX can revert central 
sensitization and its associated allodynia.
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INTRODUCTION
The TRPV1 receptor is an important nonselective 
cation channel belonging to the TRP family and ex‑
pressed at the central and peripheral terminals of the 
sensory neurons. It is considered to be a key receptor 
involved in the transmission and modulation of pain 
signals and is an important transducer of stimuli (Vidal 
2004, Latorre et al. 2007). Thus, pharmacological mod‑
ulation of the TRPV1 receptor has been identified as 
a promising therapy for pain control (Jara‑Oseguera 
et al. 2008, Wong and Gavva 2009) and the therapeutic 
potential of many TRPV1 agonists and antagonists are 
being investigated in preclinical and clinical trials (see 
Szallasi and Sheta 2012).
Resiniferatoxin (C37H40O9), a diterpene with a mo‑
lecular mass of 628.71 g/mol, a TRPV1 agonist, isolated 
from Euphorbia resinifera, has an effect similar to cap‑
saicin, such as pungency, inflammation and changes in 
body temperature (Hergenhahn 1975, Szallasi and Blum‑
berg 1990) however, its desensitizing effect is greater 
than capsaicin (Szallasi and Blumberg 1990), as well as 
being the most potent among all the endogenous and 
synthetic TRPV1 receptor agonists (Brown et al. 2015). 
It is important to highlight the high selectivity for the 
sensory nerve terminals expressing TRPV1 receptors, 
without affecting proprioception and motor function 
(Neubert et al. 2003, Karai et al. 2004). The intrathecal 
administration is noteworthy, which has advantages in 
selective targeting and permanent exclusion of TRPV1 
receptors (Karai et al. 2004, Jeffry et al. 2009, Brown et 
al. 2015), representing a viable and versatile approach 
to pain control, because it does not present important 
side effects or tolerance, as the opioid receptors (Iadaro‑
la and Mannes 2011).
In the present study, we investigated the therapeu‑
tic effect of intrathecal RTX on the development of me‑
chanical allodynia induced by the chronic pain model 
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by the constriction of the sciatic nerve. In addition, we 
examined the level of TRPV1 expression in dorsal root 
ganglia (DRG).
METHODS
The experiments were conducted using 160 male 
Swiss mice (25g) from the main animal house of the 
Universidade Federal de Alfenas (protocol 571/2014, 
CEUA‑UNIFAL‑MG). Animals were housed in a cage un‑
der controlled temperature (24 ± 2C) and on a 12‑hour 
light‑ dark cycle (dark cycle beginning at 7 pm) and 
had free access to food and water. The guidelines of the 
Committee for Research and Ethical Issues of IASP were 
followed throughout the experiments. Each mouse was 
used only once.
The neuropathic animals were divided into two 
groups, subdivided into four groups: previous treat‑
ment group (PRE‑group; pretreated with vehicle or RTX 
and sham operated; pretreated with vehicle or RTX and 
neuropathic) and late treatment group (POST‑group; 
sham operated and treated with vehicle or RTX, neuro‑
pathic and treated with vehicle or RTX).
Model of neuropathic pain
We used the experimental model of chronic con‑
striction injury of the sciatic nerve (CCI) (Malmberg 
and Basbaum 1998). After inhalation anesthesia (2% 
isoflurane), the lateral surface of the right hind thigh 
was shaved, and we performed antisepsis of the skin of 
animals followed by the incision of the femoral mus‑
cle, exposing the three branches of the sciatic nerve. 
This model consists of moorings 1/3 to 1/2 of the dorsal 
portion of the sciatic nerve with 5.0 suture. The mus‑
cle and skin were sutured after the procedure. Animals 
were considered to be in neuropathic pain when they 
exhibited mechanical allodynia i.e., paw flinching be‑
havior response to the application of a bending force of 
less than 2 g after 72 hours of CCI.
The control experimental group consisted of sham 
operated animals (SHAM), the incision was made and 
sciatic nerve was exposed similarly to the CCI group, but 
without tying this nerve.
Drugs and intrathecal administration
RTX (Sigma ‑ Aldrich, St. Louis, MO) 1 mg was dis‑
solved in 0.1 ml of 95% ethanol and 0.9 ml of saline to 
a concentration of 1 µg/µL and stored at ‑20°C (Lee 
et al. 2012). The concentration of 2 µg in 5 µL (2 µl 
solution added 3 µl of saline) was intrathecally admin‑
istered. The control group received the same volume 
of saline. The route of administration used was intra‑
thecal (Papir‑Kricheli et al. 1997). The animals were 
anesthetized with inhaled isoflurane 2% and shaved in 
the lower back. With the spinal column arched, a 25‑ 
gauge hypodermic needle was inserted into the sub‑
arachnoid space at the level of the lower sacral spinal, 
at midline, with an angle of 45 o between L4 and L5 
vertebrae.
The PRE‑group received RTX or vehicle 1 hour before 
CCI or SHAM. The POST‑group received RTX or vehicle af‑
ter 72 hours of CCI or SHAM (Fig. 1).
Fig. 1. Intrathecal Resiniferatoxin experimental protocols. Sham (SHAM); 
chronic constriction injury (CCI); PRE‑ and POST‑treatment with intrathecal 
RTX or VEHICLE; Times for Von Frey evaluation (VF); Times of dorsal root 
ganglia extraction (DRG); Baseline 1 (B1); Baseline 2 (B2); 1 hour (T1); 
3 hours (T3); 5 hours (T5); 7 hours (T7); 12 hours (T12) and 24 hours (T24).
Behavioral tests
Mechanical stimulation test was performed by the 
same researcher. The mechanical allodynia thresholds of 
the animals were evaluated according to the up‑and‑down 
method (Chaplan et al. 1994) using the Von Frey filaments 
test (North Coast Medical, Inc. Morgan Hill, CA). Each 
mouse was placed under a transparent plastic dome on 
a metal mesh floor for 15min. The Von Frey filaments was 
applied to the plantar surface of the right hind paw for 
4 seconds or until the animals showed nociceptive behav‑
ior, characterized by the paw withdrawal, licking of the 
same and/or “flinch”. We started with the filament of 
0.4 g and a maximum of 6 assessments per animal were 
made, with 10 second intervals.
Western Blotting
The animals were anaesthetized (Isoflurane 2%, in‑
halation), in times B1, B2, T1, T5 and T24, in order to 
5_1097_Parisi_v5.indd   318 21/12/17   22:48
Antiallodynic effect of resiniferatoxin on neuropathic pain 319Acta Neurobiol Exp 2017, 77: 317–322
evaluate the expression of the TRPV1 receptors. They 
were then trichotomized in the dorsal‑lumbar re‑
gion, and a posterior‑medial incision was performed, 
followed by the opening of the plans until the bone 
blade and a laminectomy was performed in order to 
view the DRG. DRG of the L5‑L4‑L6 segments were 
dissected and posteriorly homogenized and lysed 
with buffer containing 50 mmol/l of Tris (pH 7.4), 
250 mmol/l of sodium chloride (NaCl), 10 mmol/l of 
sodium ethylenediaminetetraacetate (EDTA) (pH 8.0), 
0.5% Nonideto P‑40 (NP40) (Sigma, USA), phenyl‑
methylsulfonyl fluoride (PMSF) 1 mmol/l, 10 μg/l of 
leupeptin, 4 mmol/l of sodium fluoride (NaF). Super‑
natants were centrifuged at 1000 g for 10 min at 4°C. 
The protein content was determined with a protein 
quantification kit by the Bradford method (Pierce, 
USA). Protein samples (20 μg/well) were separated 
through electrophoresis in acrylamide gel SDS‑PAGE 
10% and transferred to nitrocellulose membranes. 
The membranes were blocked by milk 5% for 60 min 
at room temperature and incubated with anti‑TRPV1 
primary antibody (1: 500, Calbiochem, Oncogene, USA, 
35 kDa) for 48 hours at 4°C with blocking buffer [PBS 
5% (p/v) of skim milk and 0.1% Tween 20]. After wash‑
ing, the membranes were incubated with anti‑rabbit 
conjugated secondary antibody HRP (1: 2000, Jackson, 
USA) and washed again. Membranes were then devel‑
oped with the chemiluminescence kit (ECL, Amershan 
Pharmacia Biotech, Little Chalfont, U.K.) as per the 
manufacturer’s instructions. The optical density ratio 
TRPV1/β‑actin was used to calculate the expression 
of the TRPV1 receptors.
Statistical analysis
Behavioral results were expressed as mean ± standard 
error of the mean (SEM) of 5‑7 animals per group. The 
analysis was done by analysis of variance (ANOVA) and 
comparisons were performed by post‑hoc test Bonferroni 
using the software Statistical Package for Social Sciences 
(SPSS) (IBM, Chicago, USA) version 15.0; the level of sig‑
nificance was set at p<0.05.
RESULTS
Neuropathic pain model
The results of the evaluation by the Von Frey test in 
the PRE‑treatment are expressed in Fig. 2. B1 represents 
the pre‑operative period (Baseline 1, before CCI surgery), 
RTX was administered shortly after this first evaluation. 
CCI or SHAM surgery were performed and B2 (Baseline 2, 
72 hours after CCI) was evaluated. The mechanical allo‑
dynia was them evaluated at T1 (1 hour), T3 (3 hours), T5 
(5 hours), T7 (7 hours), T12 (12 hours) and T24 (24 hours) 
after B2.
In the B2 period, it was possible to observe the 
decreased threshold for the CCI/VEHICLE group, 
whereas for the SHAM/RTX and SHAM/VEHICLE 
groups the thresholds were not altered. For the CCI/
RTX PRE‑treatment group, a significant increase in 
nociceptive threshold was observed shortly after ad‑
ministration of RTX, with this increase remaining 
throughout all evaluations, demonstrating the an‑
tiallodynic effect of RTX for PRE‑treatment in CCI‑ 
neuropathic pain.
Fig. 2. Effects of the previous treatment (PRE‑group) with vehicle or RTX 
(2 µg, i.t), agonist for the TRVP1 receptor, on the nociceptive threshold 
evaluated by the Von Frey filaments in animals submitted to sham 
(SHAM) or chronic constriction injury (CCI) surgery. Data represent 
the mean ± SEM of the average nociceptive threshold (g) performed 
before CCI or SHAM surgery (B1) and after 72 hours (B2), 1 hour (T1), 
3  hours (T3), 5  hours (T5), 7  hours (T7), 12  hours (T12) and 24  hours 
(T24) after B2. The curves were significantly different with regard to 
treatment (F3,286=220.41, p<0.05) and time (F7,28=18.38, p<0.05) and 
show a  significant treatment X time interaction (F21,286=36.32, p<0.05). 
P<0.05 compared to SHAM/VEHICLE (*) or any other group (#) using the 
Bonferroni post hoc test.
Fig. 3 demonstrates the nociceptive thresholds eval‑
uated in the POST‑treatment group. For this group, B1 
represents the pre‑operative period (Baseline 1, before 
CCI surgery), B2 (Baseline 2, 72 hours after CCI) and 
RTX was administered shortly after this second evalu‑
ation. After RTX injection the mechanical allodynia was 
evaluated at T1 (1 hour), T3 (3 hours), T5 (5 hours), T7 
(7 hours), T12 (12 hours) and T24 (24 hours). In the CCI/
RTX group, neuropathic pain was reversed after 1 hour 
(T1) of the receptor agonist TRVP1, RTX persisting up to 
24 hours (T24). In the CCI/VEHICLE group, the nocicep‑
tive threshold decreased from B2 when compared to B1, 
indicating mechanical allodynia. In the SHAM/VEHICLE 
and SHAM/RTX groups the nociception thresholds were 
not altered.
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TRPV1 Expression
Fig. 4 represents Western Blotting analysis of TRPV1 
receptor expression compared to B‑actin found in DRG 
of animals submitted to the experimental model of neu‑
ropathic pain, CCI and intrathecal administration of RTX 
at times B1 (before CCI), B2 after 72 hours (CCI or SHAM), 
T1 (1hr), T5 (5hr) and T24 (24hr). TRPV1 receptor expres‑
sion decreased significantly at T1, T5 and T24 times for 
the POST‑treatment RTX group when compared to the 
vehicle group. PRE‑treatment not changed the TRPV1 
expression.
DISCUSSION
The results obtained in this work demonstrate that 
the intrathecal administration of RTX, as a previous 
and late treatment, after the model of neuropathic pain 
induced by CCI, significantly induces antiallodynia in 
this model. This idea is supported by experimental data 
demonstrating that chronic hyperalgesia induced by 
nerve damage releases several inflammatory mediators, 
which sensitize TRPV1 receptors in a constant manner 
(Kissin et al. 2007). This sensitization induces an in‑
crease in TRPV1 receptor expression in the primary af‑
ferent terminals, a fact that demonstrates that this re‑
ceptor is involved in the process of induction and main‑
tenance of neuropathic pain (Kanai et al. 2005). Thus, 
using a TRPV1 receptor antagonist, such as capsazepine, 
would be a possible treatment for inflammatory and 
neuropathic hyperalgesia (Caterina et al. 1997, Kawao 
et al 2002, Honore et al. 2005). However, blocking these 
receptors can lead to changes in body temperature (Ca‑
terina et al. 1997), therefore, the use of an agonist to 
treat neuropathic hyperalgesia induced by increased 
expression and number of receptors seems to be a pro‑
posal to increase pain sensation (Haanpää and Treede 
2012). Therefore, the particularity of the potency of the 
action of RTX (Lee et al. 2012, Brown et al. 2015) leads to 
a constant depolarization and sustained inactivation of 
the receptor reducing hyperalgesia (Szallasi and Blum‑
berg 1990). One of the main findings of this work was to 
demonstrate, for the first time in this model, that RTX 
causes a persistent nociceptive threshold increase.
Kanai et al. (2005) demonstrated in a study with rats 
with neuropathic hyperalgesia through the CCI model 
that the levels of TRPV1 expression in the spinal cord 
after CCI, quantified by Western blotting analysis were 
significantly increased on the ipsilateral side of the 
lumbar spine within 14 days after CCI surgery, but not 
on the contralateral side, results evidencing increased 
TRPV1 sensitization in the development and/or main‑
tenance of mechanical allodynia in the CCl model. The 
results of this study show that mice submitted to CCI 
model presented hyperalgesia and mechanical allody‑
nia evaluated by Von Frey filaments test, as well as the 
increased expression of TRPV1 receptors, by Western 
blotting analysis.
Fig.  4. Expression of TRPV1 receptors compared to B‑actin found in the 
DRG of times B1, B2, T1, T5 and T24 after CCI in the VEHICLE or PRE‑ and 
POST‑treatment with intrathecal RTX. At least six slices from three mice 
were examined, and the data represent the mean ± SEM. P<0,05 in t test 
regarding the relationship to the treatment group when compared to the 
CCI/VEHICLE group (*).
Fig. 3. Effects of the late treatment (POST‑group) with the vehicle and RTX 
(2 µg, i.t.), an agonist of the TRVP1 receptor, on the nociceptive threshold by 
the Von Frey filaments test in animal submitted to sham (SHAM) or chronic 
constriction injury (CCI) surgery. Data represent the mean ± SEM of the 
average nociceptive threshold (g) performed before CCI or SHAM surgery 
(B1) and after 72 hours (B2), 1 hour (T1), 3 hours (T3), 5 hours (T5), 7 hours 
(T7), 12 hours (T12) and 24 hours (T24) after the administration of the RTX 
or VEHICLE. The curves were significantly different with regard to treatment 
(F3,286=4.21, p<0.01) and time (F7,28=8.83, p<0.05) and show a  significant 
treatment X time interaction (F21,286=22.28, p<0.01). P<0.05 compared to 
SHAM/VEHICLE (*) or any other group (#) using the Bonferroni post hoc test.
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In contrast to the present study, Zhang et al. (2014) 
evaluated the antiallodynic effect of capsaicin adminis‑
tered intrathecally 3 days after the neuropathic pain model 
(CCI) in rats that no significant effect on the mechanical 
response threshold was observed, only thermal hyperalge‑
sia, and can be justified by the fact that RTX is a more po‑
tent analogue than capsaicin (Szallasi and Blumberg, 1990). 
However, one study evaluated the systemic performance of 
capsaicin, and may act punctually when administered oral‑
ly (Caterina and Julius 2001). Systemic effects are not ob‑
served with topical administration. Vidal (2004) concluded 
in a systematic review, on the efficacy of topical adminis‑
tration of capsaicin to 0.075% for the treatment of neuro‑
pathic pain, as a viable therapeutic alternative. Distinctly, 
RTX provides a long‑lasting local action with no major sys‑
temic effects (Kissin et al. 2005).
Although there is a long way to go and many studies are 
still needed to evaluate the therapeutic potential of TRPV1 
agonist drugs, a new approach to pain management arises 
from detailed research on capsaicin, RTX and other vany‑
loids in its physiological actions and its molecular binding 
to TRPV1 receptor (Iadarola and Mannes 2011). Therefore, 
studies that administered RTX intrathecally demonstrate 
the advantages in selective targeting and permanent exclu‑
sion of TRPV1 receptors, with a long‑acting antiallodynic 
effect (Lee et al. 2012, Brown et al. 2015) These observations 
support the route of administration adopted by the present 
study in which the increased expression of TRPV1 after CCI 
was prevented by intrathecal RTX treatment.
Similarly, Brown et al. (2015) investigated the electro‑
physiological effects of intrathecal administration of RTX, 
demonstrating that the drug leads to the prolonged selec‑
tive opening of the TRPV1 receptor ion channel potential, 
located primarily in the C‑fibers of the primary afferent 
nociceptive neurons, promoting the desensitization of this 
receptor and consequently analgesia and anesthesia, which 
decreases the nociceptive threshold of the animals submit‑
ted to CCI. These researchers also reported a sequence of 
animal studies that explored the use of intrathecal RTX to 
control the spontaneous pain of bone cancer in dogs. Be‑
havioral tests were performed to establish paw withdrawal 
latency, and subsequent general anesthesia was induced 
for the administration of RTX intrathecally, with hemody‑
namic parameters being monitored, the authors conclud‑
ed that intrathecal RTX causes transient hemodynamic 
effects, and produces a prolonged antiallodynic response.
Lee et al. (2015) demonstrated the antiallodynic effect 
of RTX on the experimental model of neuropathic pain by 
spinal nerve ligation model in rats. The nociceptive paw 
withdrawal threshold was assessed through Von Frey fila‑
ments test and the animals were treated with epidural RTX 
at a concentration of 1 μg/μl. Among their findings, a sig‑
nificant increase in the nociceptive threshold was observed 
from the treatment, demonstrating RTX antiallodynic ef‑
fect. These results support the present study, even though 
it was performed with another experimental model and an‑
other route of administration of RTX. Similarly Brown et al. 
(2015) demonstrated that the administration of RTX, guid‑
ed by computed tomography, in DRG, is able to reduce the 
nociceptive transmission in pigs and after four weeks, the 
reduction of TRPV1 expression and reduction of nocicep‑
tion was verified. Also, no side effects were observed, such 
as impairment in motor function. Similarly, Lee et al. (2012) 
presented a study that evaluated the action of RTX in the 
control of neuropathic pain in rats, using the technique of 
Von Frey filaments test for the evaluation of mechanical 
allodynia, reporting that after 15 minutes of the RTX appli‑
cation (≥1 μg), an increase in the nociceptive threshold was 
observed, similar to our study, which used the same form of 
evaluation, applied concentrations close to RTX with sim‑
ilar effects.
It is important to emphasize that the use of the RTX 
concentration should be carefully administered because 
some studies have shown that high doses (≥10 μg) may not 
be beneficial (Jeffry at al. 2009, Lee et al. 2012), and it is 
also believed that the intrathecal form of administration 
is more advantageous, since this form presents a selective 
segmentation and permanent exclusion of TRPV1 recep‑
tors with antiallodynic effects of long duration (Karai et al. 
2004, Brown et al. 2015).
The choice of previous RTX treatment was based on 
studies demonstrating this TRPV1 agonist in pain man‑
agement (Kissin et al. 2005, Lee et al. 2012). Thus, Meller et 
al. (1992) demonstrated the preventive effect on thermal 
hyperalgesia, neonates were treated with capsaicin, and 
this prevented the development of thermal hyperalgesia 
produced by constrictive ligatures around the sciatic nerve 
18 weeks later (Shir and Seltzer 1990), similarly to studies 
by Gaus et al. (2003), in which capsaicin administered in‑
traperitoneally before CCI prevented the development of 
thermal hyperalgesia. In analogy, Kissin et al. (2005) veri‑
fied the induction of short thermal and mechanical hypoal‑
gesia after RTX application. In his work the application was 
performed via perineural as a treatment prior to incisional 
pain. Corroborating with the results found in the present 
study, in which the RTX obtained antiallodynic effect in 
the previous treatment evaluated in a short period of time, 
without altering the expression of TRPV1 receptors in GDR.
To date, there are no data in the literature demonstrat‑
ing the administration of RTX in clinical trials. Iadarola and 
colleagues (2011) encouraged the search for clinical trials 
in humans, initiating research on the use of RTX to demon‑
strate its efficacy and safety.
Although the participation of the TRPV1 receptor in the 
nociceptive mechanisms has been widely demonstrated 
(Julius 2001, Neubert et al. 2003, Karai et al. 2004, Kissin et 
al. 2005, Jeffry et al. 2009, Iadarola and Mannes 2011, Lee et 
al. 2012, Brown et al. 2015) the present study significantly 
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amplifies the understanding of the function of this recep‑
tor in the neuropathic pain model by CCI, besides evidenc‑
ing the increase of the nociceptive threshold through prior 
and late treatment of RTX intrathecally.
Through the presented findings, it is possible to show 
that RTX works effectively in the promotion of analgesia; 
however, we suggest new studies with a longer time of ob‑
servation in an attempt to clarify the mechanisms, dura‑
tion and effect of the therapy.
CONCLUSION
The presented data demonstrated that both PRE‑ 
and POST‑treatment with RTX given intrathecally pro‑
duced potent antiallodynic activities in CCI mice and that 
POST‑treatment can reduce TRPV1 expression in DRG, sug‑
gesting that POST‑treatment RTX can revert central sensi‑
tization and its associated allodynia.
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